Evaluating cognitive profiles of patients undergoing clinical amyloid-PET imaging

• DOI: 10.1093/braincomms/fcab035
• Publication Date: 2021-03-10T20:13:42Z
• Authors: Flavia Loreto; Stephen Gunning; Mara Golemme; Hilary Watt; Neva Patel; Zarni Win; Christopher Carswell; Richard J Perry; Paresh A Malhotra
• Keywords: Amyloid (mycology)

Episodic memory impairment and brain amyloid-beta are two of the main hallmarks Alzheimer's Disease. In clinical setting, these often evaluated through neuropsychological testing amyloid PET imaging, respectively. The use in practice is only indicated patients with substantial diagnostic uncertainty due to atypical presentation, multiple comorbidities and/or early age onset. relationship between cognition has been previously investigated, but no study examined how features relate presence pathology population that meets appropriate criteria for imaging. this study, we a cohort (n = 107) who presented at Imperial Memory Clinic were referred assessment as part their workup. We compared cognitive performance amyloid-positive (Aβ-pos, n 47) stable amyloid-negative (stableAβ-neg, 26) progressive (progAβ-neg, 34) patients. group performed significantly worse than both groups visuospatial working domains. performance, however, effectively differentiated from not group. On affective questionnaires, reported higher levels depression our cohort, dysfunction better indicators positivity episodic dysfunction. These findings highlight limited value isolated scores